Popular
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
DKA in Focus: What the New Consensus Means for Practice
CME/CEDKA in Focus: What the New Consensus Means for Practice
Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD
Jennifer Sherr, MD, PhD
Why Adenoma Detection Rate Matters in Colorectal Cancer Screening
Clinician's RoundtableWhy Adenoma Detection Rate Matters in Colorectal Cancer Screening
Brian P. McDonough, MD, FAAFP
Renee Williams, MD, GI
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Programs
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Maria Pabon, MD
Robert J. Mentz, MD, FHFSA, FACC
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
Brian P. McDonough, MD, FAAFP
Raja-Elie E. Abdulnour, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS
Anjali Owens, MD
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Clinical Practice
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
Rethinking Cardiovascular Risk: Uncovering the Blind Spots
Conversations in CV Risk AssessmentRethinking Cardiovascular Risk: Uncovering the Blind Spots
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Leveraging CGM to Its Full Potential in People with T2D
CME/CELeveraging CGM to Its Full Potential in People with T2D
John E. Anderson, MD
Davida F. Kruger, CNP
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Juan Badimon, PhD, FAHA
Doctors Lounge
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
Ryan Quigley
Samuel Muench, MD
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Brian P. McDonough, MD, FAAFP
Jean-Claude Saghbini
Navigating Vaccine Communication: A Medical Affairs Perspective
MAPSChatsNavigating Vaccine Communication: A Medical Affairs Perspective
Matt Birnholz, MD
Abigail Sporer, PhD, MBA
Collaboration in Medical Affairs: Increasing Value and Impact
MAPSChatsCollaboration in Medical Affairs: Increasing Value and Impact
Matt Birnholz, MD
Renu Juneja, PhD
Matt Birnholz, MD
Justin O’Rourke, PhD, MBA
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
Matt Birnholz, MD
Brandon Young, PhD
CME
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
CME/CEApplying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
Lewis S. Blevins, Jr, MD
James W. Suliburk, MD, FACS
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
Anjali Owens, MD
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
CME/CELiving With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Cem Akin, MD, PhD
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc
Anjali Owens, MD
Escalate With Intention: Stepwise, Target-Anchored Moves
MinuteCE®Escalate With Intention: Stepwise, Target-Anchored Moves
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Industry Feature
Primary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Conversations in CV Risk AssessmentPrimary Care and Cardiology: Shared Responsibility in Albuminuria Detection
Jennifer Caudle, DO, FACOFP
Javed Butler, MD, MPH, MBA
Martha Gulati, MD, MS, FACC
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Charles Turck, PharmD, BCPS, BCCCP
George Grossberg, MD
Angela Sanford, MD, CMD
Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
Medical Industry FeatureUnderstanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Medical Industry FeatureTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Expanding Treatment Options in PNH: Expert Approaches to Personalized Care
Medical Industry FeatureExpanding Treatment Options in PNH: Expert Approaches to Personalized Care
Caroline Piatek, MD
Bhumika Patel, MD
Long-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Medical Industry FeatureLong-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Arati Chand, MD
Bhumika Patel, MD